Last reviewed · How we verify
NCT04605523
Neurofilament Light- Chain in Ataxia Telangiectasia
trial testing blood withdrawal in Ataxia Telangiectasia in 40 participants. Status unknown.
31 December 2020
Quick facts
| Lead sponsor | Johann Wolfgang Goethe University Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 40 |
| Start date | 1 February 2020 |
| Primary completion | 31 December 2020 |
| Estimated completion | 31 December 2020 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- blood withdrawal — full drug profile →
Conditions studied
- Ataxia Telangiectasia — all drugs for Ataxia Telangiectasia →
Sponsor
Johann Wolfgang Goethe University Hospital
Who can join
Adults 2 to 45, any sex, with Ataxia Telangiectasia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Ataxia telangiectasia (A-T) is a rare autosomal recessive neurodegenerative disorder characterized by progressive cerebellar ataxia, immunodeficiency, chromosomal instability, and cancer susceptibility. Currently there are no curative therapy options. The clinical presentation of the disease has a wide variety is linked to the proven mutation, immunological status and residual ATM kinase activity. Apart from these prognostic markers, hardly any biomarker to predict disease course is available. Aim of the present proposal is to evaluate serum concentrations of neurofilament - light chain in the serum of whole blood as biomarker of neurodegeneration prospectively. In addition to that, the investigators will examine the evolution of neurofilament - light chain longitudinally by blood samples from our biobank as well as the concentration of neurofilament - light chain in cerebrospinal fluid (CSF) of affected A-T patients from our biobank. As in other neurodegenerative disorders and ataxias, the investigators expect that neurofilament- light chain levels are increased in the A-T cohort and correlated to the neurological status of A-T patients evaluated by means of AT-score.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04605523
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of blood withdrawal
Trials testing the same drug.
- NCT07518069 — Genetic and Biohumoral Factors Involved in Menière's Disease and Their Correlation With Phenotypes · recruiting
- NCT03727399 — Identification of Allergen-reactive Antibodies in the Blood of Pollen Allergic Patients · enrolling by invitation
- NCT05370105 — Extracellular Vesicles as Stroke Biomarkers · completed
- NCT03079518 — Intravenous Iron in paTients With Heart failURe and Reduced Ejection fracTion (HFREF) pLus Iron dEficiency · Phase 2 · completed
- NCT02708368 — SOP's for CKD-MBD-Biomarkers · completed
Other recruiting trials for Ataxia Telangiectasia
Currently open trials in the same condition.
- NCT04870866 — NAD Supplementation to Prevent Progressive Neurological Disease in Ataxia Telangiectasia · Phase 2 · active not recruiting
Other Johann Wolfgang Goethe University Hospital trials
Trials by the same sponsor.
- NCT05921136 — Recycling Potential in Endoscopy - a Multicentre Prospective Observational Study · unknown
- NCT04739020 — Respiratory Aerosols in Patients With COVID-19 and Healthy Controls · NA · unknown
- NCT04975490 — Characterization and Pathogenesis of ACLF · unknown
- NCT04546867 — Establishing a Sonographic Based Algorithm to Verify Pancreatic Stent Position Placed to Prevent Post-ERCP Pancreatitis · NA · completed
- NCT04476498 — Prospective Comparison of Pull-PEG and Pull-PEG With Gastropexy · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04605523 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Johann Wolfgang Goethe University Hospital
- Last refreshed: 30 October 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04605523.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing